Toxicity

Baron & Budd Shareholder Holly Werkema Receives 2024 Compassionate Counsel Award

Retrieved on: 
Friday, March 22, 2024
Medical Devices, Health, Professional Services, Pharmaceutical, Legal, Toxicity, Baron, Baron & Budd, P.C., Trauma, Lawyer, P.C, Seventh Amendment, Milestone

is pleased to announce that shareholder Holly Werkema has been named to the 2024 class of Compassionate Counsel honorees.

Key Points: 
  • is pleased to announce that shareholder Holly Werkema has been named to the 2024 class of Compassionate Counsel honorees.
  • Compassionate Counsel recipients are selected by The Milestone Foundation’s board for their unwavering commitment to the tenets of the Seventh Amendment and belief in the fundamental right to justice.
  • Over the course of her career, Ms. Werkema has worked tirelessly representing clients in complex multi-district litigation involving a number of high-profile pharmaceutical defendants.
  • For more information about The Milestone Foundation’s Compassionate Counsel awards, visit https://themilestonefoundation.org/compassionate-counsel/ .

AstraZeneca to acquire Fusion to accelerate the development of next-generation radioconjugates to treat cancer

Retrieved on: 
Tuesday, March 19, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Toxicity, Radiation, Prostate cancer, AstraZeneca, Patient, RCS, Acquisition, Cancer, Actinium-225, PSMA, Investment, Antibody, VWAP, Peptide, Medical imaging

AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs).

Key Points: 
  • AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs).
  • These medicines deliver a radioactive isotope directly to cancer cells through precise targeting using molecules such as antibodies, peptides or small molecules.
  • The acquisition brings new expertise and pioneering R&D, manufacturing and supply chain capabilities in actinium-based RCs to AstraZeneca.
  • RCs combine the precise targeting of antibodies, small molecules or peptides with potent medical radioisotopes to deliver radiation directly to cancer cells.

Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates

Retrieved on: 
Monday, March 18, 2024
Biotechnology, Neurology, Health, Pharmaceutical, Clinical Trials, Toxicity, Administration, Information technology, MECP2, Inc., Patient, Cash, Batten disease, Cohort, Female, Insurance, Rett syndrome, Research and development, Investment, Clinical trial, Net, Data, DSM-IV codes, Pharmaceutical industry

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced fourth quarter and full year 2023 financial results and highlighted recent corporate updates.

Key Points: 
  • Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced fourth quarter and full year 2023 financial results and highlighted recent corporate updates.
  • We believe this expanded dataset will support future regulatory discussions to align on the design of a potential registrational study,” said Rachel McMinn, Ph.D., Chief Executive Officer and Founder of Neurogene.
  • “NGN-401 has the potential to be a best-in-class treatment option with a targeted route of administration to deliver full-length, functional copies of the MECP2 gene.
  • Net income for the three months ended December 31, 2023 included a one-time $16.4 million bargain purchase gain related to the reverse merger.

India Water Treatment Chemicals Industry Report 2024: Stringent Environmental Regulations and Increased Awareness Boosts Sector Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, March 15, 2024
Utilities, Other Natural Resources, Sustainability, Energy, Technology, Food, Beverage, Natural Resources, Environment, Retail, Chemicals, Plastics, Food Tech, Manufacturing, GxP, Toxicity, Health, INR, Growth, Urbanization, Acceleration, Bacteria, Water purification, Water quality, Water, Safety, Power, Population growth, Disinfectant, Sewage treatment

The water treatment chemicals sector involves manufacturing and supplying a wide range of chemical products for treating and purifying water in diverse applications.

Key Points: 
  • The water treatment chemicals sector involves manufacturing and supplying a wide range of chemical products for treating and purifying water in diverse applications.
  • These chemicals are utilized in municipal water treatment, industrial processes, wastewater treatment, and other sectors to improve water quality, ensure its safety for consumption, and mitigate environmental impacts.
  • Stringent environmental regulations and increased industry awareness are anticipated to drive significant growth in the wastewater treatment chemicals market.
  • Increasing power plants, coupled with a focus on operational efficiency, drive the demand for water treatment chemicals to optimize cooling and boiler feedwater treatment.

Global Bispecific Antibody Market, Drugs Sales, Patent, Price & Clinical Trials Insight 2029: Pioneering New Drug Class with Versatile Therapeutic Potential - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 14, 2024
Other Health, Health, Science, Pharmaceutical, Research, Multiple myeloma, Toxicity, Antigen, Haemophilia A, Cell, Autoimmunity, Patent, Carcinoma, Risk, Inflammation, Haemophilia, Malignancy, Monoclonal antibody, Neoplasm, Tissue, Patient, Tumor microenvironment, Antibody, Cancer, Bladder cancer, Leukemia, Diabetic retinopathy, Indication, Cytokine, Immune system, Therapy, Infection, Priority, Physician, Engineering, Escape Room, Acute lymphoblastic leukemia, Vaccine

The "Global Bispecific Antibody Market, Drugs Sales, Patent, Price & Clinical Trials Insight 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Bispecific Antibody Market, Drugs Sales, Patent, Price & Clinical Trials Insight 2029" report has been added to ResearchAndMarkets.com's offering.
  • Bispecific antibodies are engineered proteins intended to simultaneously bind two different antigens, typically found on distinct cell types.
  • Therefore, bispecific antibodies have demonstrated enough clinical success to validate their potential as a major new drug class.
  • Global Bispecific Antibody Market, Drugs Sales, Patent, Price & Clinical Trials Insight 2029 Report Highlights:
    Bispecific Antibodies Development Proprietary Platforms Insight: > 30 Platforms
    Global Bispecific Antibodies Market Size 2023: > USD 8 Billion
    Clinical & Commercial Insight on Approved Bispecific Antibodies: 12 Antibodies
    Global Bispecific Antibodies Clinical Trials by Company, Indication & Phase: > 800 Antibodies
    FDA & EMA Fast Track Approval, Orphan Designation, Priority Status Insights

GGWP Now Protects and Nurtures Player Experiences For Over 25 Game Companies

Retrieved on: 
Wednesday, March 13, 2024
Technology, Electronic Games, Social Media, Entertainment, Online, Mobile Entertainment, General Entertainment, Artificial Intelligence, Software, Networks, Communications, Internet, Security, Consumer Electronics, Cloud, Toxicity, Communication, PC, Growth, Sandbox, VR, Survival, Environment, Cooperative, Safety, Warhammer 40,000: Darktide, Video game

GGWP now helps more than 25 iconic companies – including thatgamecompany, Unity, Dreamhaven, Fatshark, Omeda Studios, and Sandbox -- protect their player experiences with proactive, AI-powered moderation and shape player behavior through prosocial reinforcement and feedback loops.

Key Points: 
  • GGWP now helps more than 25 iconic companies – including thatgamecompany, Unity, Dreamhaven, Fatshark, Omeda Studios, and Sandbox -- protect their player experiences with proactive, AI-powered moderation and shape player behavior through prosocial reinforcement and feedback loops.
  • Additionally, for triaged events for manual review, the GGWP platform facilitates a reduction of average review time by 75% for these prioritized cases.
  • “Healthy communities and safety are critical to the player experience in games and online worlds,” said Dennis Fong, co-founder of GGWP.
  • Since it became free to implement in August, GGWP has seen notable growth across various gaming genres, including first-person shooters, survival crafting games and VR experiences.

Valoir Report shows HR is not ready for AI

Retrieved on: 
Tuesday, March 12, 2024
Technology, Human Resources, Consulting, Professional Services, Software, Internet, Data Analytics, Data Management, Artificial Intelligence, Workforce, Automation, Bias, Toxicity, HR, Organization, Policy, Hallucination, AI

AI-fueled automation may be inevitable, but human resources departments aren’t necessarily ready, finds a new global report by Valoir.

Key Points: 
  • AI-fueled automation may be inevitable, but human resources departments aren’t necessarily ready, finds a new global report by Valoir.
  • The survey of more than 150 HR Executives finds tremendous AI opportunities but also a general lack of policies, practices and training to safely and effectively adopt AI for HR.
  • “HR departments that address these issues and mitigate risks can see significant benefits from AI.”
    The report finds 35% of HR employees’ workday is ripe for automation.
  • HR leaders ranked lack of AI skills and expertise as the highest barrier to AI adoption, yet only 14% of organizations have a training policy for effective AI use.

Nutcracker Therapeutics to Present Data on mRNA Drug Candidate and Immunomodulatory Cytokine at AACR 2024

Retrieved on: 
Tuesday, March 12, 2024
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Online, Toxicity, Nutcracker, Prostate cancer, RNA, Cervical intraepithelial neoplasia, Abstract, AACR, Therapy, Antigen

The first presentation entails LIGHT, an immunomodulatory cytokine that is one of the components of NTX-250, the company’s lead candidate for cervical intraepithelial neoplasia.

Key Points: 
  • The first presentation entails LIGHT, an immunomodulatory cytokine that is one of the components of NTX-250, the company’s lead candidate for cervical intraepithelial neoplasia.
  • The second presentation is on preclinical data for Nutcracker’s mRNA drug candidate for prostate cancer, NTX-470.
  • This therapy is designed to target prostate cancer antigens with mRNA-encoded, multi-specific T cell engagers with a strong anti-tumor effect and low toxicity.
  • The 2024 AACR Annual Meeting takes place in San Diego from April 5-10.

MaaT Pharma Announces Long Term Follow-Up Data for MaaT013 in Early Access Program to be Presented at the Upcoming EBMT Conference

Retrieved on: 
Tuesday, March 12, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Rated R, Toxicity, Survival, ASH, Hematology, Risk, Patient, Hospital, ARES, EAP, Policy, Cancer, Quality of life, MET, DSMB, D28, Pharmaceutical industry

Details from the presentation will be disclosed in a press release on April 17th, 2024, in compliance with the conference embargo policy.

Key Points: 
  • Details from the presentation will be disclosed in a press release on April 17th, 2024, in compliance with the conference embargo policy.
  • Aligned with its mission to enhance the survival of cancer patients, MaaT Pharma has been actively involved in the EAP in Europe since 2019.
  • The Company has consistently presented real-world data from its EAP at major hematology conferences over the past four years.
  • To date, over 220 patients have been treated with MaaT013 in Europe in clinical trials and the EAP.

INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO

Retrieved on: 
Monday, March 11, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Toxicity, Catholic higher education, Congress, Survival, Partnership, Patient, Doxorubicin, Doctor of Philosophy, Overalls, PROC, Clinical trial, Paclitaxel, ESGO, Pharmaceutical industry

Novocure (NASDAQ: NVCR) today announced a late breaking abstract which reviews the results of an exploratory subgroup analysis of the phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 (INNOVATE-3) clinical trial has been selected for presentation at the “Best Oral Session – Late Breaking Abstracts” on Sunday, March 10, 2024 at the European Society on Gynaecological Oncology (ESGO) 2024 Congress in Barcelona.

Key Points: 
  • Novocure (NASDAQ: NVCR) today announced a late breaking abstract which reviews the results of an exploratory subgroup analysis of the phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 (INNOVATE-3) clinical trial has been selected for presentation at the “Best Oral Session – Late Breaking Abstracts” on Sunday, March 10, 2024 at the European Society on Gynaecological Oncology (ESGO) 2024 Congress in Barcelona.
  • Of the 558 total patients enrolled in the INNOVATE-3 clinical trial, 201 patients (36%) were PLD-naïve.
  • “We are extremely pleased to share these data with our colleagues at ESGO and humbled by the selection for a best oral presentation session,” said primary investigator Professor Ignace Vergote, MD, PhD, Professor at the Catholic University of Leuven, Belgium.
  • “I would like to thank our collaborators, ENGOT and The GOG Foundation, for their partnership designing and conducting the INNOVATE-3 trial.